|
|
|
|
|
Nadolol
drug data and news
Nadolol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Nadolol | ||
| Brand Names/Synonyms | Anabet; CCRIS 1048; Corgard; Corzide; HSDB 6532; Nadolol; Nadolol [Usan:Ban:Inn:Jan]; Nadololum [Inn-Latin]; Solgol | ||
| Indication | For the treatment of arrhythmias, angina pectoris, and hypertension | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. | ||
| Mechanism Of Action | Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. | ||
| Nadolol News (When available) |
Ask the Clinician: Answers to Readers' Questions Feb 20, 2006 King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006 Just see, before it catches you Dec 9, 2005 Pediatric Patients with Refractory Headache Respond to Zonisamide ... Oct 17, 2005 To: National Desk, Health and Consumer Reporter Mar 28, 2005 Lower-Cost Drugs Can Help Heart Patients Apr 1, 2005 Management of Hypertension in Older Persons Feb 21, 2005 BCBSNC Launches New Prescription Drug Savings Initiative Feb 17, 2005 | ||
| Dosage Forms | Tablets (20 mg, 40 mg, 80 mg, 120 mg, and 160 mg) | ||
| Drug_Category | Sympatholytics; Antihypertensive Agents; Anti-Arrhythmia Agents; Adrenergic beta-Antagonists; ATC:C07AA12 | ||
| Absorption | Absorption of nadolol after oral dosing is variable, averaging about 30 percent. | ||
| Interactions |
Interactions for Nadolol: When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics. Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia; adjust dosage of antidiabetic drug accordingly. Catecholamine-depleting drugs (e.g., reserpine): additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension). Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. | ||
| Toxicity | Oral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-(2-hydroxy-3-tert-butylamino-propoxy)tetralin-2,3-diol | ||
| Chemical Formula | C17H27NO4 | ||
| Molecular Weight | 309.401 g/mol | ||
| Smiles String | CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O | ||
| Melting Point | 124-136 °C | ||
| Water Solubility | 8330 mg/L | ||
| State | Solid (white crystalline powder) | ||
| LogP/Hphobicity | 1.398 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not metabolized by the liver and excreted unchanged primarily by the kidneys. | ||
| Half Life | 14-24 hours | ||
| Protein Binding [%] | 30% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Nadolol.html http://www.rxlist.com/cgi/generic3/nadolol.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cor1102.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00301 | ||
| CAS Registry Number | 42200-33-9 | ||
| KEGG Compound ID | D00432 | ||
| PubChem ID | SID:180211 | ||
| PharmGKB ID | PA450573 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 818704 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |